India Exchange Filings

Sai Life Sciences Q2 Earnings and Board Meeting Highlights

Sai Life Sciences Ltd reports Q2 FY27 consolidated revenue of ₹658.6 crore and net profit of ₹98.3 crore

  • Revenue rose 22.5% year on year and 18.8% sequentially; net profit increased 17.3% year on year and 34.2% sequentially.
  • Calculated consolidated EBITDA margin was approximately 28.3%; no exceptional items were reported.
  • Board approved unaudited Q2 and half-year results ended 30 September 2026; limited-review conclusion was unmodified.
  • Appointed three senior management personnel and approved allotment of 1,08,005 shares on exercise of employee stock options.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.